Cargando…
The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report
BACKGROUND: Primary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high deg...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185818/ https://www.ncbi.nlm.nih.gov/pubmed/37205183 http://dx.doi.org/10.3389/fonc.2023.1094770 |
_version_ | 1785042439823687680 |
---|---|
author | Fu, Shujuan Wang, Zhiying Li, Cunya Li, Yun Zhang, Ke Zhong, Zhixian Zhong, Yi |
author_facet | Fu, Shujuan Wang, Zhiying Li, Cunya Li, Yun Zhang, Ke Zhong, Zhixian Zhong, Yi |
author_sort | Fu, Shujuan |
collection | PubMed |
description | BACKGROUND: Primary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high degree of malignant invasion. The median survival time of NUT carcinoma patients is 6 to 9 months, and 80% of the patients die within 1 year after diagnosis. CASE DESCRIPTION: This case report summarizes the treatment of a 36-year-old male patient with NUT carcinoma of the right parotid gland. The overall survival of the patient was 2 years. We also discuss the applications and outcomes of immune checkpoint inhibitor and targeted therapy combination regimens in the treatment of NUT carcinoma. CONCLUSION: We suggest that targeted therapy combined with immunotherapy which has long-term clinical benefits and targeted therapy which has high clinical response rate(immunotherapy + dual-targeting three-drug regimens) is an ideal choice for the treatment of patients with rare and/or refractory tumors and will not compromise patient safety. CLINICAL TRIAL REGISTRATION: identifier ChiCTR1900026300. |
format | Online Article Text |
id | pubmed-10185818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101858182023-05-17 The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report Fu, Shujuan Wang, Zhiying Li, Cunya Li, Yun Zhang, Ke Zhong, Zhixian Zhong, Yi Front Oncol Oncology BACKGROUND: Primary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high degree of malignant invasion. The median survival time of NUT carcinoma patients is 6 to 9 months, and 80% of the patients die within 1 year after diagnosis. CASE DESCRIPTION: This case report summarizes the treatment of a 36-year-old male patient with NUT carcinoma of the right parotid gland. The overall survival of the patient was 2 years. We also discuss the applications and outcomes of immune checkpoint inhibitor and targeted therapy combination regimens in the treatment of NUT carcinoma. CONCLUSION: We suggest that targeted therapy combined with immunotherapy which has long-term clinical benefits and targeted therapy which has high clinical response rate(immunotherapy + dual-targeting three-drug regimens) is an ideal choice for the treatment of patients with rare and/or refractory tumors and will not compromise patient safety. CLINICAL TRIAL REGISTRATION: identifier ChiCTR1900026300. Frontiers Media S.A. 2023-05-02 /pmc/articles/PMC10185818/ /pubmed/37205183 http://dx.doi.org/10.3389/fonc.2023.1094770 Text en Copyright © 2023 Fu, Wang, Li, Li, Zhang, Zhong and Zhong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Fu, Shujuan Wang, Zhiying Li, Cunya Li, Yun Zhang, Ke Zhong, Zhixian Zhong, Yi The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report |
title | The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report |
title_full | The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report |
title_fullStr | The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report |
title_full_unstemmed | The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report |
title_short | The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report |
title_sort | whole treatment process and thinking of a patient with nut carcinoma of the parotid gland: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185818/ https://www.ncbi.nlm.nih.gov/pubmed/37205183 http://dx.doi.org/10.3389/fonc.2023.1094770 |
work_keys_str_mv | AT fushujuan thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT wangzhiying thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT licunya thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT liyun thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT zhangke thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT zhongzhixian thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT zhongyi thewholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT fushujuan wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT wangzhiying wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT licunya wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT liyun wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT zhangke wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT zhongzhixian wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport AT zhongyi wholetreatmentprocessandthinkingofapatientwithnutcarcinomaoftheparotidglandacasereport |